Top

Published in:

01-04-2012 | Breast Oncology

Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period

Authors: Lucio Fortunato, MD, Alessandra Mascaro, MD, Igor Poccia, MD, Renato Andrich, MD, Mostafà Amini, MD, Leopoldo Costarelli, MD, Giuliana Cortese, MD, Massimo Farina, MD, Carlo Vitelli, MD

Published in: Annals of Surgical Oncology | Issue 4/2012

Abstract

Background

Invasive lobular carcinoma (ILC) is believed to be more often multicentric and bilateral compared with invasive ductal cancer (IDC), leading clinicians to pursue a more aggressive local and contralateral approach.

Methods

Retrospective review of a consecutive cohort of breast cancer patients operated at one institution from January 2000 to January 2010 was performed. Median follow-up was 4 years.

Results

There were 171 ILC (14.5%) and 1,011 IDC patients in the study period. Median age (63 vs. 65 years) and tumor diameter (1.7 cm) were similar in the two groups. Diagnoses of ILC were more frequent in the second half of the study period (55/465 vs. 116/662, p < 0.01). Multicentricity was reported in 108/1,011 (10.6%) IDC and in 31/171 (18.1%) ILC patients (p < 0.01). A positive margin of resection at initial surgery was documented in 71/1,011 (7%) IDC and in 21/171 (12.3%) ILC patients (p < 0.001). Although the rate of mastectomy decreased over time in both groups, this was more pronounced for ILC patients (p < 0.001). Locoregional control, contralateral cancer, overall survival, disease-free survival, and survival according to diameter, nodal status, and type of surgical intervention did not differ between IDC and ILC. On multivariate analysis, stage of disease and hormone receptor status were associated with disease-free survival, but histology was not.

Conclusions

Although ILC is more often multicentric, bilateral, and associated with a positive margin of resection, local control and survival are similar to IDC. ILC can be treated similarly to IDC with good results.

Foote FW Jr, Stewart FW. A histologic classification of carcinoma of the breast. Surgery. 1946;19:74–99.PubMed

Bouvet M, Ollila DW, Hunt KK et al. Role of conservation therapy for invasive lobular carcinoma of the breast. Ann Surg Oncol. 1997;4:650–54.PubMedCrossRef

Orvieto E, Maiorano E, Bottiglieri L et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast. Cancer. 2008;113:1511–20.PubMedCrossRef

Chung MA, Cole B, Wanebo HJ, Bland KI, Chang HR. Optimal surgical treatment of invasive lobular carcinoma of the breast. Ann Surg Oncol. 1997;4:545–50.PubMedCrossRef

Molland JG, Donnellan M, Janu NC, Carmalt HL, Kennedy CW, Gillett DJ. Infiltrating lobular carcinoma—a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. The Breast. 2004;13:389–96.PubMedCrossRef

Sastre-Garau X, Jouve M, Asselain B, et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996;77:113–20.PubMedCrossRef

Mallon E, Varga Z: relapse of invasive lobular carcinoma. Breast Dis. 2009;30:53–6.PubMed

Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149–56.PubMedCrossRef

McGuire KP, Santillan AA, Kaur P. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16:2682–90.PubMedCrossRef

10.

Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.PubMedCrossRef

11.

Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy. Cancer. 2003;98:697–702.PubMedCrossRef

12.

Winchester DJ, Chang HR, Graves TA, Menck HR, Bland KI, Winchester DP. A comparative analysis of lobular and ductal carcinoma of breast: presentation, treatment, and outcomes. JACS. 1998;186:416–22.

13.

Salvadori B, Biganzoli E, Veronesi P, et al. Conservative surgery for infiltrating lobular breast carcinoma. Br J Surg. 1997;84:106–9.PubMedCrossRef

14.

Yeatman TJ, Lyman GH, Smith SK, Reintgen DS, Cantor AB, Cox CE. Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. Ann Surg Oncol. 1997;4:198–202.PubMedCrossRef

15.

Peiro G, Bornstein BA, Connolly JL. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat. 2000;59:49–54.PubMedCrossRef

16.

Mersin H, Yildrim E, Gulben K, Berberoglu U: Is invasive lobular carcinoma different from invasive ductal carcinoma? EJSO. 2003;29:390–5.PubMed

17.

Santiago RJ, Harris EER, Qin L. Similar long-term results of breast-conservation treatment for stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast. Cancer. 2005;103:2447–54.PubMedCrossRef

18.

Vo TN, Meric-Bernstam F, Yi M, et al. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg. 2006;192:552–5.PubMedCrossRef

19.

Fritz P, Klenk S, Goletz S, et al. Clinical impacts of histological subtyping primary breast cancer. Anticancer Res. 2010;30:5137–44.PubMed

20.

Fortunato L, Mascaro A, Amini M, Farina M, Vitelli CE. Sentinel lymph node biopsy in breast cancer. Surg Oncol Clin North Am. 2008;17:673–99.CrossRef

21.

Mann RM. The effectiveness of MR Imaging in the assessment of invasive lobular carcinoma of the breast. Magn Reson Imaging Clin North Am. 2010;18:259–76.CrossRef

22.

Furman B, Gardner MS, Romilly P, et al. Effect of 0.5 Tesla magnetic resonance imaging on the surgical management of breast cancer patients. Am J Surg. 2003;186:344–7.PubMedCrossRef

23.

Brem RF, Ioffe M, Rapelyea JA, Yost KG, Weigert JM, Bertrand ML, Stern LH. Invasive lobular carcinoma; detection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR. 2009;192:379–83.PubMedCrossRef

24.

Siegmann KC, Baur A, Vogel U, Kraemer B, Hahn M, Claussen CD. Risk–benefit analysis of preoperative breast MRI in patients with primary breast cancer. Clin Radiol. 2009;64:403–13.PubMedCrossRef

25.

Wagner PL, Kitabayashi N, Chen YT, Shin SJ. Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast. A molecular study of 10 cases. Am J Clin Pathol. 2009;132:871–6.PubMedCrossRef

26.

De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenina in invasive lobular breast canceer and lobular carcinoma in situ. J Pathol. 1997; 183:404–11.PubMedCrossRef

27.

Cleton-Jansen AM. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res. 2002;4:5–8.PubMedCrossRef

28.

Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975;36:1–85.PubMedCrossRef

29.

Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000;88:2561–69.PubMedCrossRef

30.

Choi YJ, Pinto MM, Hao L, Riba AK. Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma. Mod Pathol. 2008;21:1224–37. Epub 2008 Jun 27.PubMedCrossRef

31.

Longacre TA, Ennis M, Quennevill LA, et al. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol. 2006;19:195–207.PubMedCrossRef

32.

Wasif N, Maggard MA, Ko CY, Giuliano AE. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol. 2010;17:1862–9.PubMedCrossRef

33.

Silverstein MJ, Lewinsky BS, Waisman JR, Gierson Ed, Colburn WJ, Senofsky GM, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 1994;73:1673–7.PubMedCrossRef

34.

Ashikari R, Huvos AG, Urban JA, Robbins GF. Infiltrating lobular carcinoma of the breast. Cancer. 1973;31:110–6.PubMedCrossRef

35.

Lesser M, Rosen PP, Kinne D. Multicentricity and bilaterality in invasive breast carcinoma. Surgery. 1982;91:234–40.PubMed

36.

Horn PL, Thompson WD. Risk of contralateral breast cancer: association with histologic, clinical, and therapeutic factors. Cancer. 1988;62:412–24.PubMedCrossRef

37.

Du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Blamey RW. Invasive lobular carcinomas of the breast—the prognosis of histopathological subtypes. Br J Cancer. 1989;60:605–9.PubMedCrossRef

38.

Mate TP, Carter D, Fischer DB, et al. A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast carcinoma. Cancer. 1986;58:1995–2002.PubMedCrossRef

39.

Hussien M, Lioe TF, Finnegan J, Spence RA. Surgical treatment for invasive lobular carcinoma of the breast. Breast. 2003;12:23–35.PubMedCrossRef

40.

Viale G, Rotmensz N, Maisonneuve P, et al. Lack of prognostic significance of ‘‘classic’’ lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat. 2009;117:211–4.PubMedCrossRef

41.

Singletary SE, Patel-Parekh L, Bland KI: Treatment trends in errly-stage invasive lobular carcinoma; A report from the National Cancer Data Base. Ann Surg. 2005;242:281–9.PubMedCrossRef

42.

Gentilini O, Botteri E, Rotmensz N, et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat. 2009;113:577–83. Epub 2008 Mar 11.PubMedCrossRef

43.

Jones NB, Wilson J, Kotur L, Stephens J, Farrar WB, Agnese DM. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol. 2009;16:2691–6. Epub 2009 Jun 9.PubMedCrossRef

44.

Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16:2697–704.PubMedCrossRef

45.

Schnitt SJ, Connolly JL, Recht A, Silver B, Harrir JR. Influence of infiltrating lobular histology on local tumor control in breast cancer patients treated with conservative surgery and radiotherapy. Cancer. 1989;64:448–54.PubMedCrossRef

46.

White JR, Gustafson GS, Wimbish K, et al. Conservative surgery and radiation therapy for infiltrating lobular carcinoma of the breast. Cancer. 1994;74:640–7.PubMedCrossRef

47.

Weiss MC, Fowble BL, Solin LJ, Yeh IT, Schultz DL. Outcome of conservative therapy for invasive breast cancer by histologic subtype. Int J Radiat Oncol Biol Phys. 1992;23:941–7.PubMedCrossRef

48.

Poen JC, Tran L, Juillard G, et al. Conservation therapy for invasive lobular carcinoma of the breast. Cancer. 1992;69:2789–95.PubMedCrossRef

49.

Santiago RJ, Wu L, Harris E, Fox J, Schultz D, Glick J, et al. Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: the University of Pennsylvania experience. Int J Radiat Oncol Biol Phys. 2004;58:233–40.PubMedCrossRef

50.

Haffty BG, Goldberg NB, Rose M, et al. Conservative surgery with radiation therapy in clinical Stage I and II breast cancer. Results of a 20-year experience. Arch Surg. 1989;124:1266–1270.PubMedCrossRef

51.

Gage I, Recht A, Gelman R, Nixon AJ, Silver B, Bornstein BA, et al. Long-term outcome following breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1995;33:245–51.PubMedCrossRef

52.

Mansfield CM, Komarnicky LT, Schwartz GF, et al. Ten-year results in 1070 patients with Stages I and II breast cancer treated by conservative surgery and radiation therapy. Cancer. 1995;75:2328–36.PubMedCrossRef

53.

Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabar L, Nordgren H, et al. 10-year results after sector resection with or without postoperative radiotherapy for Stage I breast cancer: a randomized trial. J Clin Oncol. 1999;17:2326–33.PubMed

54.

Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med. 2003;163:2149–53.PubMedCrossRef

55.

Allemani C, Sant M, Berrino F, et al. Prognostic value of morphology and hormone receptor status in breast cancer—a population-based study. Br J Cancer. 2004;91:1263–8.PubMedCrossRef

56.

du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Robertson JG, et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol. 1991;17:251–7.PubMed

57.

Mhuircheartaigh JN, Curran C, Hennessy E, Kerin MJ. Prospective matched-pair comparison of outcome after treatment for lobular and ductal breast carcinoma. Br J Surg. 2008;95:827–33.PubMedCrossRef

58.

Jayasinghe UW, Bilous AM, Boyages J. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma? Breast J. 2007;13:479–85.PubMedCrossRef

Title: Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period
Authors: Lucio Fortunato, MD
Alessandra Mascaro, MD
Igor Poccia, MD
Renato Andrich, MD
Mostafà Amini, MD
Leopoldo Costarelli, MD
Giuliana Cortese, MD
Massimo Farina, MD
Carlo Vitelli, MD
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 4/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1907-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2012

Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer

Changes in Myostatin Signaling in Non-Weight-Losing Cancer Patients

Adverse Features on Rectal MRI Identify a High-risk Group that May Benefit from More Intensive Preoperative Staging and Treatment

The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones

The Combined Expression of Metaplasia Biomarkers Predicts the Prognosis Of Gastric Cancer

High Serum Hyaluronic Acid and HBV Viral Load are Main Prognostic Factors of Local Recurrence after Complete Radiofrequency Ablation of Hepatitis B-Related Small Hepatocellular Carcinoma